CAUSAL GENES AND PATHOGENIC MECHANISMS UNDERLYING GASTROINTESTINAL DISEASES
Professor Mauro D’Amato
Professor of Medical Genetics, Department of Medicine and Surgery,
LUM University in Casamassima, Italy &
Ikerbasque Research Professor and Head of the Gastrointestinal Genetics Lab
CIC bioGUNE, Derio, Spain
RESEARCHER PROFILE
Filmed online | January 2025
Mauro D’Amato is Professor of Medical Genetics at the Department of Medicine and Surgery at LUM University in Casamassima – Italy, and Ikerbasque Research Professor and Head of the Gastrointestinal Genetics Lab in CIC bioGUNE, Derio – Spain. His career has developed through an important international trajectory, holding research and academic positions at several institutions including the Wellcome Trust Center for Human Genetics in Oxford – UK, the Karolinska Institutet in Stockholm – Sweden, Biodonostia HRI in San Sebastian – Spain and Monash University in Melbourne – Australia.
Professor D’Amato has more than 25 years research experience in the field of human genetics and complex diseases, with activities most recently geared towards a translational application for therapeutic precision in gastroenterology. His team, the Gastrointestinal Genetics Laboratory, combine leading expertise in genomic, computational and pre-clinical research, and have contributed important breakthroughs linking specific genes and pathogenetic mechanisms to a number of gastrointestinal diseases like inflammatory bowel disease (IBD), microscopic colitis (MC) and irritable bowel syndrome (IBS).
He is also the coordinator of the bellygenes initiative on the genetics of IBS, and biobank-scale research from his lab contributes to multiple scientific consortia and collaborative networks studying the genetic makeup of millions of people across EU, USA and Australasia.
Professor D’Amato has an H-index of 74, has edited 2 books and published extensively in the field of human genetics and gastrointestinal disease; he provides expert feedback to international journals and research funding agencies, and has supervised more than 40 PhD students and postdocs.
https://orcid.org/0000-0003-2743-5197
-
Earlier identification and early intervention for children who are deaf or hard of hearing
As Director of NextSense Institute, Professor Leigh is responsible for leading the not-for-profit organisation’s world-class research and education programs and facilities. He has held a variety of positions in the education of children who are deaf or hard of hearing before entering academia. He holds a degree in Special Education from Griffith University, a Master of Science (Speech and Hearing) from Washington University and a PhD in Special Education from Monash University. In 2001, he was made a Fellow of the Australian College of Educators and in 2014, he was invested as an Officer in the Order of Australia (AO) for distinguished services to the deaf and hard of hearing community.
-
Using Gut Microbes to Reduce Blood Pressure
Professor Francine Marques is an National Health and Medical Research Council Emerging Leader, Viertel Charitable Foundation, and National Heart Foundation Fellow.
She leads the Hypertension Research Laboratory at Monash University and has published more than 120 peer-reviewed papers in journals such as Nature Reviews Cardiology, Nature Medicine, Nature Cardiovascular Research, and Circulation.
-
Benefits of prehabilitation ahead of surgery
Dr Matthew Wallen PhD, AES, AEP is a Senior Research Fellow in Cancer Survivorship, the Deputy Lead of the Cancer Survivorship Program, and a Senior Lecturer in Exercise Science and Clinical Exercise Physiology within the College of Nursing and Health Sciences at Flinders University, in South Australia. His clinical interest focuses on improving outcomes for people requiring major surgery, specifically (1) lifestyle interventions, including exercise, nutritional, and psychological support to improve the health and wellbeing of people prior to surgery, termed ‘prehabilitation’, (2) novel physical function assessments aimed at identifying people at risk of treatment-related complications, and (3) implementation of new models of care in cancer.
